Federal psychedelic policy in June 2026 tracks shifting U.S. action on rescheduling, veterans' access, research pathways, and competing state-federal priorities

Federal psychedelic policy in June 2026 centers on how U.S. agencies, lawmakers, and advocates are shaping access to psychedelic-assisted care, research, and drug scheduling. National attention appears focused on the tension between expanding clinical interest and the slower pace of federal rulemaking, reimbursement, and regulatory change. Congressional activity, veterans' policy, and agency decisions likely form the backbone of the update, with particular emphasis on pathways for MDMA and psilocybin, the role of ketamine in existing medical practice, and the legal barriers that still limit broader implementation. State-level reforms add pressure by moving faster than Washington on supervised access and therapeutic pilots. Federal choices matter because scheduling, FDA pathways, VA policy, and research approvals determine whether psychedelic treatment remains confined to small programs or can scale into mainstream healthcare. The wider consequence is a growing mismatch between public demand, clinical evidence, and the institutions that control lawful access.